Wever, information is still limited on 1516647 the intake of flavonoids and each flavonoid subclass in the United States and worldwide. More carefully designed studies should be performed to improve the method and database for assessing dietary flavonoids intake. Menopausal status and estrogen-receptor (ER) status, as effect modifiers, may greatly effect the association between the flavonoid intake and breast cancer risk. Some studies showed that the association between the intake of soy isoflavone and the reduced risk of breast cancer incidence or recurrence was stronger in postmenopausal women than in premenopausal women [42,43]. Although the other flavonoid subclasses have weaker phytoestrogen activity than iso125-65-5 flavones, the menopausal status and ER status also influence their association with breast cancer. The present analysis indicates a significant association of flavonol, flavone and flavan-3-ol intake with the reduced risk of breast cancer in postmenopausal but not in pre-menopausal women. The possible mechanism might partially lie in that flavonoids affect the ovariansynthesis of sex hormones or the alteration of other menstrual cycle characteristics [44,45]. Although flaonoids, especially isoflavones, are most widely recognized for their weak estrogenic activity, they have a variety of other biologic activities that may influence cancer risk, such as antioxidant, antiproliferative, [46] and antiangiogenic activities [47] as well as inhibiting the effects of cytokines, growth factors, and several enzymes [48,49]. The anticancer effects of flavonoids may be exerted by the combination of a variety of biologic activities, and would be influenced by some established risk factors for cancer such as alcohol consumption [50], smoking status, energy intake, menopausal status, use of hormonal treatment for menopause et al [51,52]. Therefore, the chemoprevention of flavonoids may be varied among different 1485-00-3 subpopulation. More carefully designed studies should be performed to investigate the association of phytochemicals with cancer.ConclusionsThe present study suggests the intakes of flavonols and flavones, but not the other flavonoid subclasses or total flavonoids, can potentially contribute to breast cancer prevention, especially among post-menopausal women. More studies are needed to confirm the findings.Author ContributionsConceived and designed the experiments: CH XQ ZJD MMT. Performed the experiments: CH PXL ZQY. Analyzed the data: CH XQ ZQY. Contributed reagents/materials/analysis tools: XQ ZQY PXL. Wrote the paper: CH ZJD MMT.
Solid tumours are commonly infiltrated by several immune cells [1?]. In cancer, immune cells play conflicting roles with potential capability either in eliminating or promoting malignancy. In contrast to infiltration of cells responsible for chronic inflammation, the presence of high numbers of lymphocytes, especially T cells, has been reported to be an indicator of good prognosis in many types of cancer [4?]. However, even if the abundance of tumour-infiltrating T-cells has been associated with improved clinical outcome, in some types of cancer, including the colorectal ones, the influence of immune cells on the prognosis is still a 
matter of debate. Although the exact mechanism remains uncertain, the adaptive immune system may play an important role in suppressing tumour progression [8]. Tumour-infiltrating T-cells may be suggestive of the host immune response to the tumour and represent attractive targets for immu.Wever, information is still limited on 1516647 the intake of flavonoids and each flavonoid subclass in the United States and worldwide. More carefully designed studies should be performed to improve the method and database for assessing dietary flavonoids intake. Menopausal status and estrogen-receptor (ER) status, as effect modifiers, may greatly effect the association between the flavonoid intake and breast cancer risk. Some studies showed that the association between the intake of soy isoflavone and the reduced risk of breast cancer incidence or recurrence was stronger in postmenopausal women than in premenopausal women [42,43]. Although the other flavonoid subclasses have weaker phytoestrogen activity than isoflavones, the menopausal status and ER status also influence their association with breast cancer. The present analysis indicates a significant association of flavonol, flavone and flavan-3-ol intake with the reduced risk of breast cancer in postmenopausal but not in pre-menopausal women. The possible mechanism might partially lie in that flavonoids affect the ovariansynthesis of sex hormones or the alteration of other menstrual cycle characteristics [44,45]. Although flaonoids, especially isoflavones, are most widely recognized for their weak estrogenic activity, they have a variety of other biologic activities that may influence cancer risk, such as antioxidant, antiproliferative, [46] and antiangiogenic activities [47] as well as inhibiting the effects of cytokines, growth factors, and several enzymes [48,49]. The anticancer effects of flavonoids may be exerted by the combination of a variety of biologic activities, and would be influenced by some established risk factors for cancer such as alcohol consumption [50], smoking status, energy intake, menopausal status, use of hormonal treatment for menopause et al [51,52]. Therefore, the chemoprevention of flavonoids may be varied among different subpopulation. More carefully designed studies should be performed to investigate the association of phytochemicals with cancer.ConclusionsThe present study suggests the intakes of flavonols and flavones, but not the other flavonoid subclasses or total flavonoids, can potentially contribute to breast cancer prevention, especially among post-menopausal women. More studies are needed to confirm the findings.Author ContributionsConceived and designed the experiments: CH XQ ZJD MMT. Performed the experiments: CH PXL ZQY. Analyzed the data: CH XQ ZQY. Contributed reagents/materials/analysis tools: XQ ZQY PXL. Wrote the paper: CH ZJD MMT.
Solid tumours are commonly infiltrated by several immune cells [1?]. In cancer, immune cells play conflicting roles with potential capability either in eliminating or promoting malignancy. In contrast to infiltration of cells responsible for chronic inflammation, the presence of high numbers of lymphocytes, especially T cells, has been reported to be an indicator of good prognosis in many types of cancer [4?]. However, even if the abundance of tumour-infiltrating T-cells has been associated with improved clinical outcome, in some types of cancer, including the colorectal ones, the influence of immune cells on the prognosis is still a matter of debate. Although the exact mechanism remains uncertain, the adaptive immune system may play an important role in suppressing tumour progression [8]. Tumour-infiltrating T-cells may be suggestive of the host immune response to the 
tumour and represent attractive targets for immu.
